Massachusetts Financial Services Co. MA Has $1.14 Million Stock Holdings in Prelude Therapeutics Incorporated (NASDAQ:PRLD)

Massachusetts Financial Services Co. MA lifted its position in shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) by 5.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 549,530 shares of the company’s stock after purchasing an additional 27,155 shares during the period. Massachusetts Financial Services Co. MA owned about 1.00% of Prelude Therapeutics worth $1,138,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in PRLD. Vanguard Group Inc. raised its position in Prelude Therapeutics by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 1,016,999 shares of the company’s stock worth $4,821,000 after purchasing an additional 10,143 shares during the last quarter. Exchange Traded Concepts LLC raised its position in shares of Prelude Therapeutics by 32.2% during the third quarter. Exchange Traded Concepts LLC now owns 64,409 shares of the company’s stock worth $133,000 after acquiring an additional 15,682 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Prelude Therapeutics by 103.2% during the second quarter. Dimensional Fund Advisors LP now owns 29,074 shares of the company’s stock worth $111,000 after acquiring an additional 14,769 shares during the last quarter. Finally, Kennedy Capital Management LLC acquired a new position in shares of Prelude Therapeutics in the first quarter worth approximately $119,000. 79.72% of the stock is currently owned by institutional investors and hedge funds.

Prelude Therapeutics Stock Performance

Shares of PRLD opened at $1.05 on Thursday. The firm has a market cap of $57.78 million, a PE ratio of -0.59 and a beta of 1.56. Prelude Therapeutics Incorporated has a 52-week low of $0.93 and a 52-week high of $6.80. The business’s 50 day moving average price is $1.60 and its two-hundred day moving average price is $3.52.

Prelude Therapeutics (NASDAQ:PRLD) last released its earnings results on Wednesday, November 6th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.05. The company had revenue of $3.00 million for the quarter. Research analysts predict that Prelude Therapeutics Incorporated will post -1.82 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have issued reports on PRLD. HC Wainwright restated a “buy” rating and set a $5.00 price target on shares of Prelude Therapeutics in a report on Friday, November 8th. JMP Securities reissued a “market outperform” rating and set a $7.00 target price on shares of Prelude Therapeutics in a research note on Monday, September 16th.

About Prelude Therapeutics

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.